FIELD: medicine.
SUBSTANCE: the present innovation deals with treating nervous-muscular diseases in mammals due to introducing therapeutically efficient amounts of inhibitor GDF-8 and corticosteroid for a person who has the risk of the development of nervous-muscular disorder or who suffers with nervous-muscular lesion - muscular dystrophy, atrophy, in particular, induced with corticosteroids, for the period of time being sufficient to maintain the desired levels of muscular functions. This provides synergistic result in improving different muscular functions.
EFFECT: higher efficiency.
28 cl, 3 dwg, 4 ex, 6 tbl
| Title | Year | Author | Number |
|---|---|---|---|
| NUETRALISING ANTIBODIES AGAINST GDF-8 AND THEIR APPLICATION | 2003 |
|
RU2360925C2 |
| IMPROVED ANTIBODIES GDF-8 ANTAGONISTS AND THEIR USE | 2013 |
|
RU2630634C2 |
| COMBINED APPLICATION OF TRAPS OF GDF AND ERYTHROPOIETIN RECEPTOR ACTIVATORS FOR INCREASING ERYTHROCYTE CONTENT | 2010 |
|
RU2592670C2 |
| COMBINED ADMINISTRATION OF GDF TRAPS AND ERYTHROPOETIN RECEPTOR ACTIVATORS FOR INCREASING CONTENT OF ERYTHROCYTES | 2010 |
|
RU2642302C1 |
| COMBINED USE OF GDF TRAPS AND ACTIVATORS OF ERYTHROPOIETIN RECEPTORS TO INCREASE ERYTHROCYTE CONTENT | 2017 |
|
RU2732229C2 |
| USE OF MYOSTATIN ANTAGONISTS, COMBINATION CONTAINING THEM AND THEIR USE | 2016 |
|
RU2781401C2 |
| COMBINED USE OF GDF TRAPS AND ERYTHROPOIETIN RECEPTOR ACTIVATORS TO INCREASE ERYTHROCYTE COUNT | 2020 |
|
RU2814047C2 |
| MEANS FOR TREATMENT OF VIOLATIONS INVOLVING RIANODIN RECEPTORS MODULATION | 2013 |
|
RU2644350C2 |
| NITROGEN OXIDE-RELEASING COMPOUNDS | 2007 |
|
RU2560144C2 |
| APPLICATION OF NITROOXYDERIVATIVE DRUG FOR TREATING MUSCULAR DYSTROPHY | 2007 |
|
RU2429828C2 |
